www.alk.net
  • Patients
    • What is allergy
      • House dust mite allergy
      •  
      • Pollen allergy
      •  
      • Living with allergy
      •  
      • Socio-economic impact
      •  
    •  
    • What is allergic asthma
    •  
    • How is allergy diagnosed
    •  
    • Treating allergy
    •  
  •  
  • Healthcare Professionals
    • Treating allergy and asthma
    •  
    • Products
    •  
    • Adverse reactions
    •  
    • Initiation of treatment
    •  
    • Clinical trials
    •  
  •  
  • R&D
    • R&D pipeline
    •  
    • Understanding immunotherapy
    •  
    • Research
    •  
    • Congress activities
    •  
    • Clinical data sharing
    •  
  •  
  • Careers
    • Working at ALK
    •  
    • Vacant positions
    •  
  •  
  • Investors
    • Overview
    •  
    • Financial reporting
      • Risk management
      •  
      • Reporting standards
      •  
      • Auditors
      •  
    •  
    • Governance
      • IR policy
      •  
      • Management
      •  
      • Board of directors
      •  
      • Annual general meeting
      •  
      • Annual general meeting (DK)
      •  
    •  
    • News & Events
      • Company Releases
      •  
      • Company releases (DK)
      •  
      • Webcasts & presentations
      •  
      • Investor calendar
      •  
    •  
    • The Share
      • Dividend history
      •  
      • Analyst coverage
      •  
      • Analyst estimates
      •  
      • Shareholder information
      •  
      • Authorizations
      •  
      • ADR Programme
      •  
    •  
    • Contact IR
    •  
    • Management
    •  
    • Board of directors
    •  
    • AGM
    •  
    • AGM (DK)
    •  
    • Nyheder
    •  
    • Nyheder (EN)
    •  
  •  
  • Media
  •  
  • About
    • ALK at a glance
    •  
    • CSR
    •  
    • Production
    •  
    • Global presence
    •  
    • Organisation
    •  
    • History
    •  
    • Values
    •  
    • Owners
    •  
  •  
  • Select country
  •  
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar

« Back

ALK updates its full-year financial outlook

November 05, 2020

PDF Version

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales. Therefore, the company is upgrading its earnings and cash flow outlook to DKK 350-400 million and approximately DKK 0, respectively, while narrowing its revenue growth outlook to around 8% organic growth.

Preliminary Q3 results show organic revenue growth in local currencies to DKK 772 million (739). This was achieved despite the continuing negative impact of COVID-19 on ALK’s legacy business, predominantly in the USA where ALK estimates missed sales due to the pandemic of more than DKK 100 million for the full year. Earnings (EBITDA) in Q3 grew by 61% to DKK 58 million (36), due to savings, operational leverage and delayed R&D expenditure.

ALK’s outlook update is as follows:

  • Organic revenue growth is expected at around 8% equating to approximately DKK 3.5 billion (previously towards the lower end of 8-12%).
  • Operating profit (EBITDA) is now expected to be DKK 350-400 million (previously 300-350).
  • Free cash flow is now expected at approximately DKK 0 million (previously negative ~200), reflecting the higher earnings and a positive change to working capital.

ALK will detail the revised full-year outlook in its nine-month interim report (Q3), which will be published Wednesday 11 November 2020, following which, the company will host a teleconference for analysts and institutional investors at 1.30 p.m. (CET).

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, mobile +45 3050 2014

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

  • FM_10_20UK_05112020
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved